Crohn's Disease

In a video exclusive, Remo Panaccione, MD, University of Calgary, discusses his research showing Skyrizi bested placebo in inducing clinical remission in patients with Crohn’s disease.

Adding surgical closure to anti-tumor necrosis factor therapy in perianal fistula demonstrates more successful and frequent healing with lower long-term perianal disease activity index, according to a presenter at UEG Week Virtual.

Abivax announced updates on ABX464 for the management of moderate to severe ulcerative colitis.

Loss of response to anti-tumor necrosis factor-alpha among patients with inflammatory bowel disease decreased in incidence following two years of treatment, according to research published in Alimentary Pharmacology & Therapeutics.

The American Gastroenterological Association published a conceptual model and clinical practice update for the prevention, detection and management of colorectal dysplasia in patients with inflammatory bowel disease.

COVID-19 mortality was not increased in patients on immunosuppressive biologics, according to a study.

Healio Gastroenterology presents the following account of our latest inflammatory bowel disease coverage.

Corticosteroid and tofacitinib use in patients with inflammatory bowel disease correlated with increased total cholesterol levels, according to research published in Alimentary Pharmacology and Therapeutics.

Adalimumab biosimilar BI 695501 demonstrated similar safety and efficacy compared with adalimumab reference product among patients with Crohn’s disease, according to research published in the Lancet Gastroenterology and Hepatology.

Cerecor reported positive initial results from a trial analyzing CERC-002 for the treatment of patients with moderate to severe Crohn’s disease, according to a press release.